Biogen Equities

Companies
Biogen (BIIB) Faces Downtrend, But a Turnaround May Be Imminent Nov 5, 2024
Companies
Biogen Reports Positive Outcomes from Higher-Dose Nusinersen Trial in SMA Treatment Sep 5, 2024
Pharmaceuticals
Biogen Announces European Approval for Tocilizumab Biosimilar, TOFIDENCE™ Jun 25, 2024
Companies
FDA Approves Eisai's LEQEMBI® Maintenance Dosing Application for Early Alzheimer's Treatment Jun 10, 2024
Pharmaceuticals
European Commission Revokes Marketing Authorizations for Generic TECFIDERA® Variants; Biogen Affected Dec 20, 2023